This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2002;288:953-954.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2002;51:598-599

Supplies of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine and measles, mumps, and rubella (MMR) vaccine in the United States have become sufficient to permit the resumption of the routine schedule for DTaP and MMR use as recommended by the Advisory Committee on Immunization Practices (ACIP).^1-3 However, health-care providers should be advised that, for the next 2 months, supply might not be adequate for the initiation of ambitious recall or special initiative programs. With increases in national inventory, more comprehensive recall programs can be established. Child care and school attendance provisions requiring children to receive a DTaP booster and a second dose of MMR vaccine at age 4-6 years can be reinstituted.

DTaP Vaccine

Three DTaP vaccines are distributed currently in the United States: Tripedia® (Aventis Pasteur, Swiftwater, Pennsylvania), Infanrix^TM (GlaxoSmithKline, Philadelphia, Pennsylvania), and DAPTACEL^TM (Aventis Pasteur, Toronto, Ontario). The Food and Drug Administration (FDA) approved . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?